

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Steven Lee Yatomi-Clarke
Date of last notice	14 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Arrow Wealth Ltd <Berbay Family A/C> (a controlled entity of Mr Yatomi-Clarke) Novetera Pty Ltd <SAYC Super Fund A/C> (a controlled entity of Mr Yatomi-Clarke) Alexandra Elizabeth Yatomi-Clarke
Date of change	4 April 2023

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p><u>Direct</u></p> <p>4,641,711 Fully paid ordinary shares 3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p><u>Indirect</u></p> <p><u>Arrow Wealth Ltd</u></p> <p>3,245,000 Fully paid ordinary shares</p> <p><u>Novetara Pty Ltd</u></p> <p>1,889,178 Fully paid ordinary shares 97,692 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024</p> <p><u>Alexandra Elizabeth Yatomi-Clarke</u></p> <p>172,500 Fully paid ordinary shares</p>
Class	<p>(a) Fully Paid Ordinary Shares (b) Listed PTXOC Options exercisable at \$0.0625 per option expiring on 31 March 2023</p>
Number acquired	<p>(a) 97,692 (b) Nil</p>
Number disposed	<p>(a) Nil (b) 97,692</p>
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<p>\$6,105.75</p>

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct</u></p> <p>4,641,711 Fully paid ordinary shares 3,500,000 Unlisted Options, exercisable at \$0.0663 (6.63 cents) per option, expiring on 2 May 2023</p> <p><u>Indirect</u></p> <p><u>Arrow Wealth Ltd</u></p> <p>3,245,000 Fully paid ordinary shares</p> <p><u>Novetera Pty Ltd</u></p> <p>1,986,870 Fully paid ordinary shares 12,900,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024</p> <p><u>Alexandra Elizabeth Yatomi-Clarke</u></p> <p>172,500 Fully paid ordinary shares</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Listed PTXOC Options into Fully Paid Ordinary Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Prescient Therapeutics Limited
ABN	56 006 569 106

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Campbell
Date of last notice	12 October 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fusion Biosciences Pty Ltd (Director and Beneficiary)
Date of change	4 April 2023
No. of securities held prior to change	Direct 242,321 Fully Paid Ordinary Shares 17,813 Listed PTXOC Options, exercisable at \$0.0625 (6.25 cents) per option, expiring on 31 March 2023 415,000 Unlisted Options, exercisable at \$0.0633 (6.63 cents) per option, expiring on 2 May 2023 Indirect <i>Fusion Biosciences Pty Ltd</i> 1,000,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024
Class	(a) Fully Paid Ordinary Shares (b) Listed PTXOC Options exercisable at \$0.0625 per option expiring on 31 March 2023

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	(a) 17,813 (b) Nil
Number disposed	(a) Nil (b) 17,813
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$1,113.31
No. of securities held after change	Direct 260,134 Fully Paid Ordinary Shares 415,000 Unlisted Options, exercisable at \$0.0633 (6.63 cents) per option, expiring on 2 May 2023 Indirect <u>Fusion Biosciences Pty Ltd</u> 1,000,000 Unlisted Options, exercisable at \$0.0968 (9.68 cents) per option, expiring on 23 November 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Listed PTXOC Options into Fully Paid Ordinary Shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.